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CORRESPONDENCE
Letters to the Editor
Cost-Effectiveness of
Cardiac Resynchronization Therapy
Recently, Feldman et al. (1) published a cost-effectiveness analysis
based on the COMPANION (Comparison of Medical Therapy,
Pacing, and Defibrillation in Heart Failure) trial, comparing cardiac
resynchronization therapy (CRT) pacemaker alone or CRT-ICD
implantable cardioverter-defibrillator versus optimal pharmacological
therapy (OPT) alone, projecting the implications of the trial over
seven years. Hlatky, in an editorial commenting on this analysis,
derived incremental cost-effectiveness ratios (ICERs) comparing
CRT-ICD to CRT pacemaker alone (2). Although we agree that
it is the ICER that is of interest, several aspects of the Feldman
analysis are of concern for this derivation.
Forcing the utility to be equal at baseline yet accepting the
nonsignificant differences observed at later time points creates a
differential quality adjustment against CRT-ICD, and this leads to
a doubling of the derived ICER. This is inappropriate as ICDs
should affect only mortality, not quality of life (3). Had the values
assigned postbaseline been equalized as could reasonably have been
assumed, the quality-adjusted life-year (QALY) estimate for
CRT-ICD would substantially increase and the ICER drop by
half.
Given that most, if not all, of the difference between the two
CRT modes is in mortality, a proper comparison would require
careful, realistic modeling of the mortality and of competing risks.
Although the model used by Feldman et al. is barely described in
the study, the investigators state that they assumed a constant
death probability per month. This sort of oversimplification has
often been felt necessary with Markov models, but does not
correctly simulate mortality and will not properly support predic-
tions of the number of lives saved by CRT-ICD over longer
periods of time.
Finally, Hlatky (2) cites as fact the $50,000 threshold for
cost-effectiveness, although this value has no basis whatsoever. A
more sophisticated approach to modeling is necessary to estimate
the potential long-term health benefits of CRT-ICD relative to
CRT alone and appropriately assess the incremental cost-
effectiveness.
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Atorvastatin in Nonischemic
Left Ventricular Systolic Dysfunction
Sola et al. (1) found that atorvastatin improved left ventricular
(LV) ejection fraction and reduced LV end diastolic dimensions in
patients with nonischemic heart failure (HF) (1). Nonischemic HF
is a heterogeneous condition with a variable clinical course. One of
the most important determinants of response to therapy is the
duration of illness. Patients with recent-onset HF due to dilated
cardiomyopathy and myocarditis have a variable clinical course,
with the most dramatic changes in LV function. They frequently
have spontaneous improvements as well as deteriorations in LV
function (2,3). In contrast, patients with long-standing disease are
likely to have relatively smaller changes in LV function spontane-
ously and in response to therapy. Patients in this study were not
randomized for the duration of illness, a very important variable.
Duration of illness may even out and not be so important a factor
in the large megatrials of HF therapy. However, in this small study
of 108 patients this important confounding variable can introduce
bias. Patients in any small study on therapeutic responses to
therapy in nonischemic HF must also be randomized for the
duration of illness.
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